Alex A. Adjei, MD; PhD; FACP; is Chairman of the Taussig Cancer Institute and the M. Frank Rudy and Margaret D. Rudy Distinguished Chair in Translational Cancer Research at Cleveland Clinic. In this role, Dr Adjei oversees cancer care and research across all Cleveland Clinic locations in Ohio, Florida, London and Abu Dhabi, UAE.

Dr. Adjei has focused his research on experimental therapeutics, regulatory science and clinical drug development and has led NCI-funded drug development teams. Other research interests include health disparities, global oncology, and pharmacogenetics.  Dr Adjei has served on a number of NCI and professional association committees. He was Chair of the NIH Study Section NCRR Clinical Research Review Committee, reviewing CTSAs. He was the President of the Minorities in Cancer Research Council of AACR and a member of the Board of Directors of IASLC, and is currently Faculty Coordinator for Developmental Therapeutics and member of the Gender Medicine Task Force of ESMO. He served on the Committee on Diagnosing and Treating Adult Cancers of the US National Academies of Sciences, Engineering and Medicine, tasked with providing a report to the US government (Social Security Administration). He is a member of the NCI Board of Scientific Counselors. He has published over 300 peer-reviewed articles. He is editor-in-chief of the Journal of Thoracic Oncology and established JTO Clinical and Research Reports, as the inaugural Editor-in-Chief.

Among numerous awards and honors, Dr. Adjei has received the Adi F. Gazdar Merit Award from the International Association for the Study of Lung Cancer for Distinguished Achievement in Lung Cancer Research and Mentorship, the ESMO Lifetime achievement award, and the ASCO Drug Development Research Professorship for his work in drug development, regulatory science and for his mentorship.